128 results
Page 5 of 7
F-3/A
EX-23.1
1xokcc2k br
16 Jul 20
Shelf registration (foreign) (amended)
9:33am
F-3/A
k1jqrn
16 Jul 20
Shelf registration (foreign) (amended)
9:33am
F-3
EX-23.1
lx8ycfm08g0sdw lmi
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
EX-5.2
n3rhe553u8 8l
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
EX-5.1
eykc0lot9x 3h3og
8 Jul 20
Shelf registration (foreign)
12:00am
F-3
e4tftsoqnjjk21
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
666ctdoh5alt 0yiak5
30 Jun 20
Current report (foreign)
6:38am
6-K
EX-99.1
4p5p xl4h
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
EX-99.2
s8ldnkno
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
nqb8zvav
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
b9br4wl1
2 Mar 20
Current report (foreign)
4:05pm
6-K
EX-99.2
363 pa2qozjv
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.3
niiyn5tg8tgd4
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
vkyv faf7e0
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
6si6b5jl7y b6s
14 Nov 19
Current report (foreign)
4:10pm
6-K
EX-99.2
eq6wirs19c9ey4m133ld
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.1
cghi9gjbxcx aooz09
7 Nov 19
Current report (foreign)
7:00am